- Home
- MGNX vs KFS Comparison
MGNX vs KFS Comparison
Compare MGNX & KFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- KFS
- Stock Information
- Founded
- MGNX 2000
- KFS 1989
- Country
- MGNX United States
- KFS United States
- Employees
- MGNX N/A
- KFS N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- KFS Property-Casualty Insurers
- Sector
- MGNX Health Care
- KFS Finance
- Exchange
- MGNX Nasdaq
- KFS Nasdaq
- Market Cap
- MGNX 257.3M
- KFS 234.2M
- IPO Year
- MGNX 2013
- KFS 1996
- Fundamental
- Price
- MGNX $3.23
- KFS $8.43
- Analyst Decision
- MGNX Hold
- KFS
- Analyst Count
- MGNX 10
- KFS 0
- Target Price
- MGNX $7.17
- KFS N/A
- AVG Volume (30 Days)
- MGNX 465.7K
- KFS 62.8K
- Earning Date
- MGNX 11-05-2024
- KFS 11-06-2024
- Dividend Yield
- MGNX N/A
- KFS N/A
- EPS Growth
- MGNX N/A
- KFS N/A
- EPS
- MGNX N/A
- KFS N/A
- Revenue
- MGNX $141,329,000.00
- KFS $108,627,000.00
- Revenue This Year
- MGNX $174.73
- KFS N/A
- Revenue Next Year
- MGNX N/A
- KFS N/A
- P/E Ratio
- MGNX N/A
- KFS N/A
- Revenue Growth
- MGNX 16.68
- KFS 2.02
- 52 Week Low
- MGNX $2.95
- KFS $7.60
- 52 Week High
- MGNX $21.88
- KFS $9.58
- Technical
- Relative Strength Index (RSI)
- MGNX 42.79
- KFS 43.78
- Support Level
- MGNX $3.10
- KFS $8.33
- Resistance Level
- MGNX $3.30
- KFS $8.50
- Average True Range (ATR)
- MGNX 0.19
- KFS 0.25
- MACD
- MGNX 0.00
- KFS 0.01
- Stochastic Oscillator
- MGNX 25.45
- KFS 45.76
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
About KFS Kingsway Financial Services Inc. (DE)
Kingsway Financial Services Inc through subsidiaries operates in the extended warranty and business services industries in the United States. The company operates through segments namely, Extended Warranty and Kingsway Search Xcelerator. The Extended Warranty segment provides after-market vehicle protection services distributed by credit unions. The firm generates maximum revenue from the Extended Warranty segment in the form of Service fee and commission income.